Having trouble reading this email? View the web version here \| Forward this email to a colleague

Bayer MaterialScience to invest €100 million in Germany

Bayer MaterialScience plans to invest roughly €100 million in the expansion of the high-tech production plant for MDI (diphenylmethane diisocyanate) at the Bayer Brunsbüttel Industrial Park in Germany...

Read more >>

More pharmaceutical & life science news:

		Takeda make donation to aid earthquake relief efforts in Japan Takeda have announced a 300 million Japanese yen donation to aid emergency relief for the earthquake on March 11...

		Bristol-Myers Squibb awards grant to the American College of Physicians Foundation ACP Foundation's initiative will address the U.S. HIV medical workforce shortage...

		Janssen Pharmaceutica NV receives offer to acquire animal health business Janssen Pharmaceutica NV has received an offer from Elanco to acquire its Janssen Animal Health business...

		Sanofi-aventis appoints Dr. Richard Klausner Sanofi-aventis is pleased to announce the appointment of Dr. Richard Klausner to Chairman of the SDSAC, effective March 1...

		Pfizer invites public to view and listen to webcast of Pfizer presentation at Healthcare Conference View and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide R&D...

		FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD An advisory committee recommended that the FDA approve QAB149 (indacaterol) in the US...

		European Commission approves XEPLION® for treatment of schizophrenia XEPLION®, has received approval from the European Commission for the treatment of schizophrenia...

		Biopharmaceutical industry changes & policies that encourage medical innovation are critical According to John Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company...

		FDA accepts new drug application for investigational compound Dapagliflozin for the treatment of type 2 diabetes The US FDA has accepted for review a New Drug Application (NDA) for dapagliflozin...

		Advanced kidney cancer patients now able to access Votrient® (pazopanib) Patients living in Scotland with renal cell carcinoma, will have access to a new treatment choice, as Votrient® (pazopanib)...

32nd ICR Annual Conference: “Patents, Pipelines & Bottlenecks: Embracing the Future”
21 - 22 March, Brighton, UK

SBS 17th Annual Conference & Exhibition Advancing the Science of Drug Discovery
27 - 31 March, Gaylord Palms Resort & Convention Center Orlando, Florida, USA

DIA 23rd Annual EuroMeeting
28 - 30 March, Geneva, Switzerland

LogiPharma Europe 2011
29 - 31 March, Geneva, Switzerland

CMC Regulatory Compliance for Biopharmaceuticals and Biologics
30 March - 1 April, Berlin, Germany

BioCapital Europe 2011
31 March, Amsterdam, Netherlands

Analytical Method Validation for Biologics, Biopharmaceuticals and Other Therapeutic Products
4 - 5 April, Berlin, Germany

Pharmaceutical and Biopharmaceutical Quality Control Laboratories - A Regulatory Compliance Primer
4 - 5 April, Dublin, Ireland

First commercially available integrated kits for isolation and detection of key contaminants in cell culture samples

Vesivirus, MMV and Mycoplasma have emerged as a potential threat to mammalian cell culture production. To meet the challenge of rapid, specific, and sensitive detection, Applied Biosystems® has developed the first commercially available integrated kits for isolation and detection of key contaminants in cell culture samples. The unique benefits are:

Only one sample extracted by PrepSEQ™ magnetic beads to test the tree contaminants at the same time.
Proprietary positive control template that helps eliminate the possibility of false positive results arising from inadvertent contamination of test samples with the positive control.

Join European Pharmaceutical Review on LinkedIn

Follow European Pharmaceutical Review on Twitter